Our study confirms that cytoplasmic and nuclear expression of CXCR4 is detectable in ccRCC and may contribute to the reduced efficacy of the ligand-based therapeutic approach. This evidence concerns the gene CXCR4 and nonpapillary renal cell carcinoma.